Sep 2026· International Journal of Molecular Sciences· Vol 27, pp. 7994· 0 citations· 47 references
Medicine
TL;DR
KJJ4 is established as a fully human anti-HTNV antibody with experimentally defined in vitro binding and neutralizing activity, warranting further evaluation in animal models of HTNV infection.
Abstract
Hantaan virus (HTNV) is the predominant causative agent of hemorrhagic fever with renal syndrome (HFRS) in China, yet no specific antiviral therapy is currently available. Neutralizing antibodies (NAbs) represent a promising strategy, but most existing anti-HTNV NAbs are heterologous and carry immunogenicity risks. Here, two fully human antibodies from a previously established human anti-HTNV phage display library were generated and characterized. KJJ3, a VL-VL tandem antibody derived from clone 3–12, showed weak binding to inactivated HTNV and minimal neutralizing activity (IC50 = 27.12 μg/mL). However, KJJ4, an engineered IgG4 antibody derived from clone 4–19 and carrying the S108P hinge mutation to prevent Fab-arm exchange, bound inactivated HTNV antigen and recombinant glycoprotein Gn (residues 19–371) in a dose-dependent manner, with only weak binding to Gc. Surface plasmon resonance yielded an association rate constant of 4.70 × 103 M−1s−1, a dissociation rate constant of 3.06 × 10−3 s−1, and an equilibrium dissociation constant of 650 nM for monomeric Gn19–371. In a Vero E6 focus-reduction microneutralization assay, KJJ4 neutralized HTNV in vitro with an IC50 of 2.879 μg/mL. These data establish KJJ4 as a fully human anti-HTNV antibody with experimentally defined in vitro binding and neutralizing activity, warranting further evaluation in animal models of HTNV infection.
The proposed MEVC demonstrated favorable predicted immunogenicity, favorable structural characteristics, broad population coverage, and favorable expression characteristics, which support experimental validation and development of a preventive strategy against Hantavirus infection.
Shahid Ullah, A. Tonks, Carlos Eliel Maya-Ramírez et al.· In Silico Pharmacology· 0 citations
It is found that several glycan cap-, GP base-, and HR2-directed antibodies cross-reacted and neutralized BDBV DRC/2026 GP pseudovirus with potency comparable to that observed against earlier BDBV isolates and the Zaire ebolavirus Makona/2024 isolate.
Amin Addetia, K. Uriu, Cameron Stewart et al.· bioRxiv· 0 citations
The continuing evolution of monkeypox virus (MPXV) clades capable of sustained human-to-human transmission poses an escalating global health risk, yet no effective therapy exists for poxvirus infection. Here, we investigate a panel of human monoclonal antibodies (mAbs), derived from an antibody library, which targets A...
Ding Zhang, R. Fantin, Xue-Yong Zhu et al.· Science immunology· 0 citations
Human noroviruses (HuNoVs) are the principal etiological agents of acute viral gastroenteritis worldwide. While conventional 96-well human intestinal organoid (HIO) neutralization assays provide a physiologically relevant assessment of neutralizing antibody (nAb) responses, sample volume requirements (50µL for 96 wells...
K. Ettayebi, M. Estes, S. Ramani et al.· Journal of Virological Metho...· 0 citations
Cryo-electron microscopy analysis revealed that 3CF5 targets a conserved non-receptor-binding epitope on the hemagglutinin (HA) head, spanning the vestigial esterase domain and an adjacent lateral surface, which mediates neutralization primarily through inhibiting membrane fusion and also possesses antibody-dependent c...
Porcine circovirus type 2 (PCV2) remains an economically significant pathogen affecting global swine herds, with emerging genetic variants raising concerns about potential immune escape from existing PCV2a-based vaccines. In this study, we identified a novel PCV2a isolate carrying four nonsynonymous substitutions (S68A...
Wen-Ting Qiao, Xin Yao, Wei Lu et al.· International Immunopharmaco...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.